Product Information
HUMULIN 70-30 VIAL is a brand product labeled by Eli Lilly and Company, priced at $4.2564 per ML under NDC 00002871501. Its NADAC has been published 671 times since Nov 28, 2013.
Strength
100 [iU]/mL
Manufacturer
Eli Lilly and CompanyNDC
00002871501
Classification
Brand
Dosage Form
INJECTION, SUSPENSION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN HUMANApproval Type
Biologic (BLA)
FDA Application
BLA019717On Market Since
6/26/1989
Pharmacological Classes
Price Statistics
The NADAC for HUMULIN 70-30 VIAL has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 47.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.2564 per ML |
|---|---|
| All-time high | $14.6189 (Jan 16, 2019) |
| All-time low | $4.2564 (Sep 23, 2026) |
| 52-week high | $4.2695 |
| 52-week low | $4.2564 |
| Median price | $14.2821 |
| Average price | $11.4335 |
| Largest weekly change | -70.0% (Jan 10, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Insulin human market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HUMULIN 70-30 VIAL?
The current National Average Drug Acquisition Cost (NADAC) for HUMULIN 70-30 VIAL, manufactured by Eli Lilly and Company, is $4.2564 per ML (NDC 00002871501), effective Sep 30, 2026.
How has the price of HUMULIN 70-30 VIAL changed over time?
Over the history we have for it, the NADAC for HUMULIN 70-30 VIAL has declined 47.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for HUMULIN 70-30 VIAL?
Since Nov 28, 2013, the NADAC for HUMULIN 70-30 VIAL has ranged from a low of $4.2564 (Sep 23, 2026) to a high of $14.6189 (Jan 16, 2019), with a median of $14.2821 per ML.
Are there cheaper alternatives to HUMULIN 70-30 VIAL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as HUMULIN 70-30 VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures HUMULIN 70-30 VIAL?
HUMULIN 70-30 VIAL (NDC 00002871501) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.